Phaseline

Companies › BioGenCell

BioGenCell: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BGC101 (autologous EnEPC preparation)
Autologous cell therapy containing endothelial progenitor cells (EnEPCs) and hematopoietic
–Phase 1Chronic Limb-Threatening IschemiaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02805023BGC101 (autologous EnEPC preparation)Phase 1Chronic Limb-Threatening IschemiaCardiovascularDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.